PTPRB and angiosarcoma: On the other hand, it has been shown that inactivating genetic mutations in the endothelial phosphatase PTPRB, another negative regulator of VEGFR-2 signaling, occur in about 26% of malign vascular tumors, named angiosarcomas [195].